LakeShore Biopharma Co., Ltd (LSB)
NASDAQ: LSB · Real-Time Price · USD
0.772
-0.037 (-4.55%)
Sep 18, 2024, 4:00 PM EDT - Market closed

LakeShore Biopharma Income Statement

Millions CNY. Fiscal year is Apr - Mar.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Mar '24 Mar '24 Mar '23 Mar '22 Mar '21
Revenue
573.42573.42687.2502.95257.02
Revenue Growth (YoY)
-16.56%-16.56%36.63%95.69%-
Cost of Revenue
187.36187.36153.36121.4659.66
Gross Profit
386.06386.06533.84381.49197.36
Selling, General & Admin
434.56434.56339.33278.76224.82
Research & Development
302.8302.8318.7211.2294.39
Other Operating Expenses
6.796.796.545.384
Operating Expenses
744.15744.15664.57495.37323.21
Operating Income
-358.09-358.09-130.73-113.88-125.85
Interest Expense
-44.34-44.34-30.86-2.72-29.69
Other Non Operating Income (Expenses)
27.4827.4817.2415.53-18.83
EBT Excluding Unusual Items
-374.96-374.96-144.35-101.07-174.37
Gain (Loss) on Sale of Investments
---137.99-130.66-16.61
Asset Writedown
-80.24-80.24---
Pretax Income
-455.19-455.19-282.34-231.73-190.98
Income Tax Expense
-21.73-21.731.134.9417.45
Net Income
-433.46-433.46-283.47-236.67-208.44
Preferred Dividends & Other Adjustments
---137.99-130.66-16.61
Net Income to Common
-433.46-433.46-145.48-106-191.83
Shares Outstanding (Basic)
107107626262
Shares Outstanding (Diluted)
107107626262
Shares Change (YoY)
73.06%73.06%-0.07%--
EPS (Basic)
-4.05-4.05-2.35-1.71-3.10
EPS (Diluted)
-4.05-4.05-2.35-1.71-3.10
Free Cash Flow
-339.48-339.48-235.23-468.86-351.49
Free Cash Flow Per Share
-3.17-3.17-3.81-7.58-5.69
Gross Margin
67.33%67.33%77.68%75.85%76.79%
Operating Margin
-62.45%-62.45%-19.02%-22.64%-48.96%
Profit Margin
-75.59%-75.59%-21.17%-21.08%-74.64%
Free Cash Flow Margin
-59.20%-59.20%-34.23%-93.22%-136.76%
EBITDA
-315.9-315.9-94.04-82.72-97.94
EBITDA Margin
-55.09%-55.09%-13.68%-16.45%-38.11%
D&A For EBITDA
42.1942.1936.6931.1527.91
EBIT
-358.09-358.09-130.73-113.88-125.85
EBIT Margin
-62.45%-62.45%-19.02%-22.64%-48.96%
Source: S&P Capital IQ. Standard template. Financial Sources.